Posts

Showing posts with the label Polyarticular Juvenile Idiopathic Arthritis (PJIA) market outlook

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Polyarticular Juvenile Idiopathic Arthritis (PJIA) Market Outlook Thelansis’s “Polyarticular Juvenile Idiopathic Arthritis (PJIA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polyarticular Juvenile Idiopathic Arthritis (PJIA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patien...

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

  Polyarticular Juvenile Idiopathic Arthritis (PJIA) Market Outlook Thelansis’s “Polyarticular Juvenile Idiopathic Arthritis (PJIA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polyarticular Juvenile Idiopathic Arthritis (PJIA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Polyarticular Juvenile Idiopathic Arthritis (PJIA) Overview Polyarticular Juvenile Idiopathic Arthritis (PJIA), a rare form of juvenile idiopathic arthritis, is characterized by the persistence of arthritis that begins before age 16 and affects at least five joints for more than six weeks within the first six months of onset. This subgroup can be divided...

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Polyarticular Juvenile Idiopathic Arthritis (PJIA), a rare form of juvenile idiopathic arthritis, is characterized by the persistence of arthritis that begins before age 16 and affects at least five joints for more than six weeks within the first six months of onset. This subgroup can be divided into two categories: one with a positive rheumatoid factor (RF) test and the other with a negative RF test. The former requires at least two RF positive tests, spaced at least 3 months apart during the initial 6-month period. Both subgroups are more prevalent among girls and may present with mild fever, weight loss, anemia, moderate hepatosplenomegaly, and mild growth retardation. Children diagnosed with polyarticular JIA often face a more challenging disease course than those with fewer affected joints. Their prolonged active disease course increases their risk of joint damage, leading to poorer functional outcomes and reduced quality of life. Key indicators of a poor prognosis for pol...